[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX370543B - Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares. - Google Patents

Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares.

Info

Publication number
MX370543B
MX370543B MX2015003970A MX2015003970A MX370543B MX 370543 B MX370543 B MX 370543B MX 2015003970 A MX2015003970 A MX 2015003970A MX 2015003970 A MX2015003970 A MX 2015003970A MX 370543 B MX370543 B MX 370543B
Authority
MX
Mexico
Prior art keywords
treatment
vegf neutralizing
prodrugs
ocular conditions
vegf
Prior art date
Application number
MX2015003970A
Other languages
English (en)
Other versions
MX2015003970A (es
Inventor
Rau Harald
Bisek Nicola
Knappe Thomas
Laufer Burkhardt
Sprogøe Kennett
Voigt Tobias
Weisbrod Samuel
Reimann Romy
Stark Sebastian
Original Assignee
Ascendis Pharma Ophthalmology Div A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Ophthalmology Div A/S filed Critical Ascendis Pharma Ophthalmology Div A/S
Publication of MX2015003970A publication Critical patent/MX2015003970A/es
Publication of MX370543B publication Critical patent/MX370543B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende uno o más excipientes farmacéuticamente aceptables y un profármaco de neutralización de VEGF, que comprende un resto biológicamente activo neutralizante de VEGF, para uso en un método para el tratamiento de una o más afecciones oculares.
MX2015003970A 2012-10-11 2013-10-08 Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares. MX370543B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12188226 2012-10-11
PCT/EP2013/070959 WO2014056923A1 (en) 2012-10-11 2013-10-08 Vegf neutralizing prodrugs for the treatment of ocular conditions

Publications (2)

Publication Number Publication Date
MX2015003970A MX2015003970A (es) 2015-07-06
MX370543B true MX370543B (es) 2019-12-17

Family

ID=47073308

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003970A MX370543B (es) 2012-10-11 2013-10-08 Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares.

Country Status (19)

Country Link
US (1) US10519226B2 (es)
EP (1) EP2906246B1 (es)
JP (1) JP2015533132A (es)
KR (1) KR102235868B1 (es)
CN (1) CN104755103A (es)
AU (1) AU2013328782C1 (es)
BR (1) BR112015007778B1 (es)
CA (1) CA2884910C (es)
DK (1) DK2906246T3 (es)
ES (1) ES2959385T3 (es)
HK (1) HK1208814A1 (es)
IL (1) IL237648B (es)
MX (1) MX370543B (es)
MY (1) MY177912A (es)
NZ (1) NZ706853A (es)
RU (1) RU2673881C2 (es)
SG (1) SG11201501914XA (es)
WO (1) WO2014056923A1 (es)
ZA (1) ZA201502410B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2643469T3 (es) 2006-04-07 2017-11-23 Aerpio Therapeutics, Inc. Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y usos de los mismos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
JP5536113B2 (ja) 2009-07-06 2014-07-02 アケビア セラピューティクス インコーポレイテッド がん細胞の転移を予防するための化合物、組成物および方法
EP2766043A4 (en) 2011-10-13 2015-06-10 Aerpio Therapeutics Inc METHOD FOR THE TREATMENT OF CAPILLARY LECKSYNDROME AND CANCER
ES2727293T3 (es) 2013-03-14 2019-10-15 Univ Massachusetts Métodos de inhibición de cataratas y presbicia
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP2988732B1 (en) * 2013-04-22 2023-05-03 Ascendis Pharma A/S Modified hydrogels
US10040850B2 (en) * 2013-10-08 2018-08-07 Ascendis Pharma A/S Protecting group comprising a purification tag
WO2015071348A1 (en) * 2013-11-18 2015-05-21 Formycon Ag Pharmaceutical composition of an anti-vegf antibody
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
WO2016073894A1 (en) * 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
MX387804B (es) 2015-09-23 2025-03-19 Aerpio Therapeutics Inc Metodos para tratar presion intraocular con activadores de tie-2
WO2017053807A2 (en) 2015-09-23 2017-03-30 Genentech, Inc. Optimized variants of anti-vegf antibodies
MX376641B (es) 2015-11-13 2025-03-07 Univ Massachusetts Moléculas bifuncionales que contienen peg para uso en la inhibición de cataratas y presbicia.
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
RU2747316C2 (ru) 2016-03-01 2021-05-04 Асцендис Фарма Боун Дизизис А/С Пролекарства pth
HUE063235T2 (hu) * 2016-09-29 2024-01-28 Ascendis Pharma Bone Diseases As Adagolási rendszer szabályozott leadású PTH vegyülethez
PL3518961T3 (pl) * 2016-09-29 2023-08-14 Ascendis Pharma Bone Diseases A/S Związki pth o niskim stosunku wartości maksymalnej do minimalnej
CA3055985A1 (en) 2017-03-22 2018-09-27 Genentech, Inc. Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
JOP20190245A1 (ar) * 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN107233570B (zh) * 2017-07-04 2021-11-23 沈阳化工大学 一种载vegf抗体的眼用温敏水凝胶植入剂及其制备方法
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
IL308797A (en) 2018-03-28 2024-01-01 Ascendis Pharma Oncology Div A/S Il-2 conjugates
US20210113660A1 (en) * 2018-05-07 2021-04-22 Olives Biotherapeutics Inc. Pharmaceutical composition comprising ccn5 as active ingredient, for preventing or treating retinal diseases
TW202027794A (zh) * 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
AU2020264969B2 (en) 2019-04-29 2025-06-05 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
CA3143435A1 (en) 2019-06-21 2020-12-24 Nicola BISEK Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
KR20230019889A (ko) 2020-06-03 2023-02-09 아센디스 파마 온콜로지 디비전 에이/에스 Il-2 서열 및 이의 용도
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003217531A1 (en) * 2002-05-02 2003-11-17 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
JP4951339B2 (ja) 2003-08-27 2012-06-13 オプソテツク・コーポレイシヨン 眼血管新生疾患の治療のための併用療法
CA2786794C (en) 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent
CA2562948A1 (en) * 2004-04-13 2005-11-24 (Osi) Eyetech, Inc. Enhanced biologically active conjugates
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
WO2007016380A2 (en) 2005-07-28 2007-02-08 (Osi) Eyetech, Inc. Cyclitol linker polymer conjugate
US8877229B2 (en) 2005-12-02 2014-11-04 Eyetech Inc. Controlled release microparticles
US20080027371A1 (en) * 2006-07-26 2008-01-31 Higuchi John W Method and device for minimally invasive site specific ocular drug delivery
HUE044174T2 (hu) * 2008-02-01 2019-10-28 Ascendis Pharma As Önhasítható linkert tartalmazó elõvegyület
ES2351919B8 (es) 2009-07-28 2012-05-30 Abengoa Solar New Technologies, S.A. Seguidor solar para módulos solares fotovoltáicos de alta concentración de tipo giratorio para cubierta y huertos solares.
WO2011012721A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Carrier linked pramipexole prodrugs
KR101770844B1 (ko) * 2009-07-31 2017-08-23 아센디스 파마 에이에스 폴리에틸렌 글리콜 기반의 생분해성 수불용성 하이드로겔
WO2011012722A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
EP2525829A1 (en) 2010-01-22 2012-11-28 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
WO2011089214A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
WO2011089216A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
EP3473249A1 (en) * 2010-03-31 2019-04-24 Wayne State University Crosslinkable dendrimers
EP2741744A1 (en) 2011-08-12 2014-06-18 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
AU2013254756B2 (en) 2012-04-25 2017-03-30 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs

Also Published As

Publication number Publication date
CA2884910C (en) 2021-07-13
US10519226B2 (en) 2019-12-31
BR112015007778A2 (pt) 2017-07-04
HK1209374A1 (en) 2016-04-01
IL237648A0 (en) 2015-04-30
EP2906246A1 (en) 2015-08-19
SG11201501914XA (en) 2015-05-28
ZA201502410B (en) 2016-01-27
AU2013328782C1 (en) 2018-01-18
DK2906246T3 (da) 2023-09-04
WO2014056923A1 (en) 2014-04-17
BR112015007778B1 (pt) 2023-04-25
CN104755103A (zh) 2015-07-01
MX2015003970A (es) 2015-07-06
CA2884910A1 (en) 2014-04-17
RU2673881C2 (ru) 2018-12-03
MY177912A (en) 2020-09-25
EP2906246B1 (en) 2023-07-26
HK1208814A1 (en) 2016-03-18
IL237648B (en) 2020-01-30
RU2015117536A (ru) 2016-12-10
KR102235868B1 (ko) 2021-04-07
AU2013328782A1 (en) 2015-03-26
KR20150065891A (ko) 2015-06-15
JP2015533132A (ja) 2015-11-19
AU2013328782B2 (en) 2017-08-10
NZ706853A (en) 2018-04-27
US20150297740A1 (en) 2015-10-22
ES2959385T3 (es) 2024-02-26

Similar Documents

Publication Publication Date Title
MX370543B (es) Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares.
MY171920A (en) Prevention and treatment of ocular conditions
PH12015500719A1 (en) Gdf-8-inhibitors
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
MX2019003249A (es) Diagnostico, prevencion y tratamiento de enfermedades de la articulacion.
IN2015DN01156A (es)
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
NZ728072A (en) Modulators of toll-like receptors for the treatment of hiv
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
MD4539B1 (ro) 4-Fenilpiridine substituite pentru tratamentul bolilor asociate cu receptorul NK-1
MX2014004862A (es) Formulaciones de polimero acrilico.
NI201000105A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada.
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
IN2014MN02236A (es)
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
WO2013171764A3 (en) Ophthalmic formulations
IN2014DN06869A (es)
EP4420722A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
PH12014502065A1 (en) Vesicular formulations
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
IN2013CH05288A (es)
UA112981C2 (uk) Варіант людського gdnf
MX2014000870A (es) Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina.
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.

Legal Events

Date Code Title Description
FG Grant or registration